(Total Views: 545)
Posted On: 06/10/2024 9:07:02 PM
Post# of 148870
FDA panel recommends Eli Lilly's early-stage Alzheimer's treatment, donanemab, for approval, despite safety concerns and deaths reported during the trial.
* Lilly's results showed a 35% reduction in progress of the disease in 18 months.
The only other drug on the market currently is Eisai and Biogen's (BIIB) Leqembi, which showed a 27% decline in progression of the disease in patients who used it for 18 months.
https://www.yahoo.com/finance/news/fda-panel-...20037.html
________________
An $875 sp company.
Gotta like how they don't call it 65% or 73% failures, for govt. $3.5b yearly cost.
Leronlimab comparison will straighten that out.
Shall see.....
* Lilly's results showed a 35% reduction in progress of the disease in 18 months.
The only other drug on the market currently is Eisai and Biogen's (BIIB) Leqembi, which showed a 27% decline in progression of the disease in patients who used it for 18 months.
https://www.yahoo.com/finance/news/fda-panel-...20037.html
________________
An $875 sp company.
Gotta like how they don't call it 65% or 73% failures, for govt. $3.5b yearly cost.
Leronlimab comparison will straighten that out.
Shall see.....
(6)
(0)Scroll down for more posts ▼
